The Double-Faced Role of Nitric Oxide and Reactive Oxygen Species in Solid Tumors.
2020
Преузимање 🢃
Аутори:
Mijatović, SanjaSavić-Radojević, Ana
Plješa-Ercegovac, Marija
Simić, Tatjana
Nicoletti, Ferdinando
Maksimović-Ivanić, Danijela
Тип документа:
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт:
Disturbed redox homeostasis represents a hallmark of cancer phenotypes, affecting cellular metabolism and redox signaling. Since reactive oxygen and nitrogen species (ROS/RNS) are involved in regulation of proliferation and apoptosis, they may play a double-faced role in cancer, entailing protumorigenic and tumor-suppressing effects in early and later stages, respectively. In addition, ROS and RNS impact the activity and communication of all tumor constituents, mediating their reprogramming from anti- to protumorigenic phenotypes, and vice versa. An important role in this dichotomic action is played by the variable amounts of O2 in the tumor microenvironment, which dictates the ultimate outcome of the influence of ROS/RNS on carcinogenesis. Moreover, ROS/RNS levels remarkably influence the cancer response to therapy. The relevance of ROS/RNS signaling in solid tumors is witnessed by the emergence of novel targeted treatments of solid tumors with compounds that target ROS/RNS action and production, such as tyrosine kinase inhibitors and monoclonal antibodies, which might contribute to the complexity of redox regulation in cancer. Prospectively, the dual role of ROS/RNS in the different stages of tumorigenesis through different impact on oxidation and nitrosylation may also allow development of tailored diagnostic and therapeutic approaches.
Кључне речи:
Cancer therapy; Nitric oxide; Reactive oxygen speciesИзвор:
Antioxidants (Basel, Switzerland), 2020, 9, 5, 374-Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200007 (Универзитет у Београду, Институт за биолошка истраживања 'Синиша Станковић') (RS-MESTD-inst-2020-200007)
DOI: 10.3390/antiox9050374
ISSN: 2076-3921
PubMed: 32365852
WoS: 000539284200017
Scopus: 2-s2.0-85084238170
URI
https://www.mdpi.com/2076-3921/9/5/374http://www.ncbi.nlm.nih.gov/pubmed/32365852
https://radar.ibiss.bg.ac.rs/handle/123456789/3673